Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025

Rhea-AI Summary

Pacira BioSciences (NASDAQ: PCRX), a leader in non-opioid pain therapies, will release its second quarter 2025 financial results after U.S. markets close on Tuesday, August 5, 2025.

The company will host a conference call and webcast at 4:30 p.m. ET the same day. Participants can pre-register for the Q&A session via telephone, while the webcast will be accessible through the "Events" page on Pacira's investor website. A replay will be available for approximately two weeks following the call.

BRISBANE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday August 5, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.

For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº^®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

Investor Contact:

Pacira BioSciences, Inc.
Christian Pedetti, (973) 254-4387
Christian.Pedetti@pacira.com

FAQ

When will Pacira (PCRX) report Q2 2025 earnings?

Pacira will report Q2 2025 earnings after U.S. markets close on Tuesday, August 5, 2025.

What time is Pacira's Q2 2025 earnings conference call?

Pacira's Q2 2025 earnings conference call and webcast will take place at 4:30 p.m. ET on August 5, 2025.

How can investors access Pacira's Q2 2025 earnings call?

Investors can pre-register for the telephone Q&A session through the provided link, or access the webcast through the 'Events' page on investor.pacira.com.

How long will Pacira's Q2 2025 earnings call replay be available?

A replay of the webcast will be available on Pacira's website for approximately two weeks following the call.